Program
mibavademab
Also written as “Mibavademab”, “REGN4461” and “Low-Dose REGN4461”.
Its studies are mostly in Obesity, Morbid · Lipodystrophy, Familial Partial · Amenorrhea · Obesity, led by 2 companies.
Drug pageMibavademab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 73 open or running | phase 3since Aug 7, 2024 | May 7, 2018 | Jun 18, 2027phase 3 · NCT07220772 |
| Eli Lillyits history only | 10 open or running | phase 2since Apr 16, 2024 | Apr 16, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 7, 2018First study: phase 1 study in Healthy VolunteersFirst studyNCT03530514 · 113 enrolled · Belgium
- Nov 7, 2019Phase 2 study in Lipodystrophy, Congenital GeneralizedNCT04159415 · 16 enrolled · United States, Peru, Russia and more
- Dec 19, 2020Named mibavademabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, REGN4461
- Oct 12, 2021Phase 2 study in Lipodystrophy, Familial PartialNCT05088460 · 20 enrolled · United States, France, Spain and more
- Aug 7, 2024Phase 3 study in Lipodystrophy, Congenital GeneralizedNCT06548100 · 9 enrolled · United States
- Oct 22, 20252 phase 3 studiesNCT07220785, NCT07220772
- Nov 14, 2025Phase 2 study in AmenorrheaNCT07235917 · 34 planned · United States
- Oct 1, 2026Primary completion moved from 2027-08-20 to 2028-01-28Date moved laterphase 2 · +5 months · NCT07235917
Ahead
- Jun 18, 2027Primary completion: phase 3 study in Obesity, MorbidNCT07220772
- Jan 28, 2028Primary completion: phase 2 study in AmenorrheaNCT07235917
- May 19, 2028Primary completion: phase 3 study in Lipodystrophy, Congenital GeneralizedNCT07220785
TargetBeta
“Leptin receptor agonist”ChEMBL 37, by rule
Studies
All 7 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07235917Amenorrhea · United States | 2 | Recruiting | Jan 28, 2028 | 34 |
| NCT07220785Lipodystrophy, Congenital Generalized · United States, Brazil, France | 3 | Recruiting | May 19, 2028 | 28 |
| NCT07220772Obesity, Morbid · Germany, Spain, Turkey (Türkiye) | 3 | Recruiting | Jun 18, 2027 | 4 |
| NCT06548100Lipodystrophy, Congenital Generalized · United States | 3 | Completed | Jul 9, 2026 | 9 |
| NCT05088460Lipodystrophy, Familial Partial · United States, France, Spain and more | 2 | Terminated | Dec 13, 2023 | 20 |
| NCT04159415Lipodystrophy, Congenital Generalized · United States, Peru, Russia and more | 2 | Completed | Jan 5, 2022 | 16 |
| NCT03530514Healthy Volunteers · Belgium | 1 | Completed | Jan 27, 2020 | 113 |
How it is read
Names in the registry
- “Mibavademab”, 4 entries
- “REGN4461”, 2 entries
- “mibavademab”, 1 entry
- “Low-Dose REGN4461”, 1 entry
- “High-dose REGN4461”, 1 entry
Conditions, from the studies’ own filings
- Obesity, Morbid, 2 studies
- Lipodystrophy, Familial Partial, 2 studies
- Amenorrhea, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.